FLEX Vascular Presents 12-Month Real-World Data for FLEX Vessel Prep System at CX Symposium 2026

Why It Matters

The data demonstrate a safe, cost‑effective alternative to drug‑coated devices, potentially lowering procedural burden and expenses for dialysis providers while improving patient outcomes.

Key Takeaways

• Zero serious adverse events at 30 days in 130 patients
• 40% primary patency in cephalic arch lesions at 12 months
• 100% secondary patency in AV grafts after one year
• Reduces reinterventions by roughly one per patient annually
• Mechanical, drug‑free KEMIC approach improves vessel compliance

Pulse Analysis

Real‑world evidence is increasingly the benchmark for evaluating vascular access technologies, especially as dialysis centers seek solutions that balance efficacy with safety. The FLEX FIRST AV Registry, encompassing 130 patients across diverse clinical settings, provides a robust data set that moves beyond the controlled environments of pivotal trials. By reporting zero serious adverse events within the first month and sustained patency rates at 12 months, FLEX Vascular offers clinicians confidence that the device performs reliably in everyday practice, a critical factor when managing the high‑risk population of end‑stage renal disease patients.

The FLEX Vessel Prep System distinguishes itself through a purely mechanical, drug‑free KEMIC (Kinetic Energy‑Modulated Intramural Compliance) approach. Unlike drug‑coated balloons or stents that introduce pharmacologic agents or permanent implants, the system gently remodels the vessel wall to enhance compliance, thereby facilitating subsequent interventions or maintaining native access. This strategy mitigates concerns about drug toxicity, delayed healing, or long‑term foreign‑body reactions, while still achieving comparable or superior patency outcomes—40% primary patency in challenging cephalic arch lesions and 100% secondary patency in arteriovenous grafts. The reduction of approximately one reintervention per patient each year translates into fewer hospital visits, lower procedural costs, and improved quality of life for patients.

For the dialysis market, these results could shift procurement and treatment algorithms toward mechanical vessel preparation as a first‑line adjunct. Cost‑containment pressures and reimbursement models that reward reduced utilization make the reported decrease in reinterventions especially compelling. As providers evaluate adoption, the combination of strong safety data, ease of integration into existing workflows, and the absence of drug‑related regulatory hurdles positions FLEX Vascular to capture a meaningful share of the growing vascular access device market. Continued post‑market surveillance will be essential, but the current evidence suggests a promising trajectory for broader clinical acceptance.